21-34792278-T-C
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 1P and 1B. PM2_SupportingBP4
This summary comes from the ClinGen Evidence Repository: NM_001754.5(RUNX1):c.1300A>G (p.Asn434Asp) is a missense variant located in exon 9. This variant is absent from all population databases, including gnomAD v2.1.1 and gnomAD v3.1.2, which provide at least 20x coverage for the RUNX1 gene at this position (PM2_supporting). It has a REVEL score of 0.169 (≤0.50), and no evidence supports an impact on splicing, as indicated by a SpliceAI score of 0.00 (BP4). This variant has not been previously reported, and no pathogenic or likely pathogenic amino acid changes have been documented at the same residue. In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PM2_supporting, BP4. LINK:https://erepo.genome.network/evrepo/ui/classification/CA410147457/MONDO:0011071/008
Frequency
Consequence
NM_001754.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Data not reliable, filtered out with message: AC0 AF: 0.00 AC: 0AN: 1388184Hom.: 0 Cov.: 33 AF XY: 0.00 AC XY: 0AN XY: 685286
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hereditary thrombocytopenia and hematologic cancer predisposition syndrome Uncertain:1
NM_001754.5(RUNX1):c.1300A>G (p.Asn434Asp) is a missense variant located in exon 9. This variant is absent from all population databases, including gnomAD v2.1.1 and gnomAD v3.1.2, which provide at least 20x coverage for the RUNX1 gene at this position (PM2_supporting). It has a REVEL score of 0.169 (≤0.50), and no evidence supports an impact on splicing, as indicated by a SpliceAI score of 0.00 (BP4). This variant has not been previously reported, and no pathogenic or likely pathogenic amino acid changes have been documented at the same residue. In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PM2_supporting, BP4. -
Hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1 Uncertain:1
While this variant is not present in population databases, the frequency information is unreliable, as metrics indicate poor data quality at this position in the ExAC database. This variant has not been reported in the literature in individuals with RUNX1-related disease. Algorithms developed to predict the effect of missense changes on protein structure and function do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This sequence change replaces asparagine with aspartic acid at codon 434 of the RUNX1 protein (p.Asn434Asp). The asparagine residue is moderately conserved and there is a small physicochemical difference between asparagine and aspartic acid. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at